Skip to main content
Hanmi Pharm. Co., Ltd. logo

Hanmi Pharm. Co., Ltd. — Investor Relations & Filings

Ticker · 128940 ISIN · KR7128940004 LEI · 988400PP10VZVUOFE672 KO Manufacturing
Open in API
Filings indexed 509 across all filing types
Latest filing 2026-02-06 Investor Presentation
Country KR South Korea
Listing KO 128940

About Hanmi Pharm. Co., Ltd.

https://www.hanmipharm.com/

Hanmi Pharm. Co., Ltd. is a research-oriented biopharmaceutical company focused on the development, manufacturing, and commercialization of pharmaceutical products. Its portfolio includes prescription drugs, over-the-counter (OTC) medicines, and raw materials. The company dedicates a significant portion of its revenue to in-house research and development, creating a robust pipeline of innovative therapies. A key unique selling point is its proprietary LAPSCOVERY platform technology, which is used to develop long-acting biologics. Hanmi's R&D efforts are concentrated on key therapeutic areas, including metabolic diseases, oncology, and rare diseases. The company actively collaborates with global partners to advance its clinical programs and bring novel treatments to the market.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최(안내공시)
Investor Presentation Classification · 98% confidence The document is a short announcement (under 1,000 characters) regarding the scheduling of an Investor Relations (IR) event (Non-Deal Roadshow). It provides details such as date, location, and purpose, and explicitly states that the actual presentation materials will be posted on the company website later. Since it is an announcement of an event rather than the presentation itself, and it serves as a regulatory notification of corporate activity, it fits the criteria for a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the specific nature of announcing an upcoming IR event, RPA is the most accurate classification.
2026-02-06 Korean
기업설명회(IR)개최(안내공시)
Investor Presentation Classification · 98% confidence The document is a short announcement (under 1,000 characters) regarding the scheduling of an Investor Relations (IR) event (Non-Deal Roadshow). It provides the date, location, and purpose of the meeting, and explicitly states that the actual presentation materials will be posted on the company website later. Following the 'Menu vs Meal' rule, this is an announcement of an event/report rather than the presentation itself, making it a Report Publication Announcement (RPA).
2026-02-06 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 95% confidence The document is a formal regulatory filing from Hanmi Pharmaceutical regarding a change in financial structure (revenue/profit/loss) exceeding 15% for a large corporation. It provides comparative financial data for the current and previous fiscal years, including revenue, operating profit, and net income. While it contains financial data, it is a specific regulatory disclosure required by the KRX (Korea Exchange) for significant financial changes, rather than a full annual report or a simple announcement of a report. Given the specific nature of this disclosure, it fits best under 'Earnings Release' (ER) as it provides the initial announcement of key financial highlights for the fiscal year. FY 2025
2026-02-05 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Preliminary Earnings Release' (잠정실적) for Hanmi Pharmaceutical. It provides key financial highlights (revenue, operating profit, net income) for the 4th quarter of 2025 and the full year. It explicitly states that these are preliminary figures subject to change upon final audit. This fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results. Q4 2025
2026-02-05 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by the National Pension Service regarding their holdings in Hanmi Pharmaceutical. This is a standard regulatory disclosure for major shareholders (10% or more) reporting changes in their share ownership, which falls under the 'Major Shareholding Notification' category.
2026-02-02 Korean
결산실적공시예고(안내공시)
Report Publication Announcement Classification · 100% confidence The document is a short announcement from Hanmi Pharm regarding the scheduled date for their upcoming financial results disclosure. It explicitly states that the actual financial results will be published on a future date (2026-02-05) and will be made available on their website. Per the 'Menu vs Meal' rule, since this is an announcement of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2026-01-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.